openPR Logo
Press release

Neuroendocrine Carcinoma Market Analysis & Key Trends 2020

01-18-2018 10:55 AM CET | Health & Medicine

Press release from: Transparency Market Research

Neuroendocrine Carcinoma Market Analysis & Key Trends 2020

A neuroendocrine tumor is a kind of tumor that begins in the hormone producing cells of the neuroendocrine system that is made up of the endocrine system and nervous system. Hormones producing neuroendocrine cells have a structure similar to neurons and produce hormones like endocrine cells. These cells are found throughout the body in organs such as intestines, kidneys, lungs and stomach and perform functions such as controlling the speed of food through gastrointestinal tract and air and blood flow through the lungs.

Report Overview @ https://www.transparencymarketresearch.com/neuroendocrine-carcinoma-market.html

Neuroendocrine tumor is a rare malignant disorder that accounts for nearly one percent of all malignant disorders. Neuroendocrine carcinomas account for nearly 60% of all neuroendocrine tumor cases and are characterized as their origin in different locations throughout the body including lungs, gastrointestinal tract and brain. Some common symptoms associated with neuroendocrine carcinoma are hyperglycemia, hypoglycemia, weight loss, loss of appetite, headache, anxiety, gastric ulcer, unusual bleeding, jaundice, diarrhea, fever and persistent in specific area.

The treatment options for neuroendocrine carcinoma include surgery, radiation therapy and chemotherapy. Chemotherapy involves the use of drugs to kill cancerous cells by inhibiting the cells ability to grow and divide. Streptozocin (Zanosar) and 5-fluorouracil (Adrucil, 5-FU) are some drugs that are used to treat neuroendocrine carcinomas. Continuous efforts by major pharmaceuticals in order to develop targeted therapy have been contributing in the growth of neuroendocrine carcinomas market. Everolimus (Afinitor) and sunitinib (Sutent) are two major targeted drugs that are being used for treating neuroendocrine carcinomas.

Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2970

Afinitor was introduced by Novartis AG in 2009 for the treatment of advanced renal cell carcinoma. This drug is useful when sunitinib or sorafenib fail to treat the renal cell carcinoma. Sutent is a brand developed by Pfizer Ltd. and is used to treat advanced renal cell carcinoma and gastrointestinal stromal tumor. F. Hoffmann-La Roche Ltd., BioSynthema, Inc., Genentech Inc. and Callisto Pharmaceuticals Pvt. Ltd. are some major companies that are striving to develop drugs for treating various neuroendocrine carcinomas. Avastin, Atiprimod and Lutathera are among other molecules that are currently being studied for their therapeutic efficacy in the treatment of neuroendocrine carcinomas.

Geographically, the market for neuroendocrine carcinoma has been segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). United States and Canada are the two major markets in North America region. North America represented the largest market for neuroendocrine carcinoma in 2013, with a largest market share in terms of revenue (USD Million). According to sources from Cancer.Net, nearly 8,000 people are diagnosed with neuroendocrine tumors every year in the United States.

Many of the key players operating in this market space are based out of U.S and thus consider North America as their primary market for product launch and investment. Also, the well established healthcare infrastructure and reimbursement scenario are among the major factors responsible for North America’s leading position in neuroendocrine carcinoma market. Europe accounted for the second largest market in 2013, followed by Asia Pacific and Rest of the World (RoW). Growing incidence of neuroendocrine carcinoma in Asia Pacific along with the improving economic scenario is likely to play a key role in driving the market growth in the region.

Pre-Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=2970<ype=S

F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Ltd., Eli Lilly & Company, Amgen, Inc., Ispen SA, Callisto Pharmaceuticals Pvt. Ltd., Bristol-Myers Squibb, Teva Pharmaceuticals, Ltd. and Biosynthema, Inc. are among others operating in the Neuroendocrine carcinoma market.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Neuroendocrine Carcinoma Market Analysis & Key Trends 2020 here

News-ID: 906712 • Views: 160

More Releases from Transparency Market Research

Hematology Diagnostics Market to Reach Approximately US$ 5,586.4 Mn by 2026
The vendor landscape of the global market of hematology diagnostics features a handful of companies collectively accounting for a large share in the overall market, hinting at a largely consolidated vendor landscape, observes Transparency Market Research in a recent report. Companies such as Sysmex Corporation, Abbott Laboratories, Beckman Coulter, Inc., F. Hoffmann-La Roche Ltd. command dominance owing to their expansive product portfolios and well-established distribution channels globally. Read Report Overview -
Endoscopic Ultrasound Needles Market to Expand at a CAGR of 4.4% from 2017 to 20 …
The global endoscopic ultrasound needles market was valued at around US$ 139.2 Mn in 2016 is anticipated to expand at a stable CAGR of over 4.5% during forecast period of 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled ’Endoscopic Ultrasound Needles Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025.’ Read Report Overview - https://www.transparencymarketresearch.com/endoscopic-ultrasound-needles-market.html Expansion of the global endoscopic ultrasound needles
Infusion Pumps Market is Projected to Expand at a Moderate CAGR of 5.40% over th …
The demand within the global market for infusion pumps has been rising on account of advancements in the domain of healthcare over the past decade, finds Transparency Market Research (TMR). The market players operating in the global market for infusion pumps have been focusing on tying up with health centers and hospitals in order to expand their market share. Read Report Overview - https://www.transparencymarketresearch.com/infusion-systems-market.html The vendors are also projected to capitalise on
Cervical Dysplasia Market Will Exhibit a Healthy CAGR of 7.2% over the Period Be …
The global market for cervical dysplasia features a highly consolidated competitive landscape, with the top three companies accounting for more than three-fourth of the overall market in 2017, observes a recent report by Transparency Market Research. These top vendors, namely Qiagen AG, Hologic Inc., and F. Hoffmann-La Roche Ltd, have strengthened their hold on the market owing to strategies such as collaboration with leading pharmaceutical and biotechnology companies and successful

All 5 Releases


More Releases for Neuroendocrine

Neuroendocrine Tumours Therapeutics Market | Global Industry Report 2019 - 2025
Neuroendocrine Tumours Therapeutics Market: Market Share, Size, Targeted Market And More Neuroendocrine tumours (NET) are the abnormal growths which begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumours are rare and can occur anywhere in the body such as small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumours can be noncancerous (benign) or cancerous (malignant). NETs will arises from several neuroendocrine cells
Will Neuroendocrine Carcinoma Market Perceive Robust Expansion by 2027?
Recently, Future Market Insights has presented value analysis and insights on the various disease types, treatment types and end users associated with the neuroendocrine carcinoma market across key regions in the globe. It has also included an in-depth analysis on the various key players participating in the global neuroendocrine carcinoma market along with key developments taking place during the 2017-2027 timeline. Future Market Insights, in its recent publication titled “Neuroendocrine
Neuroendocrine Carcinoma-Market Insights, Epidemiology and Market Forecast-2025
"The Report Neuroendocrine Carcinoma-Market Insights, Epidemiology and Market Forecast-2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" ​DelveInsights Neuroendocrine Carcinoma-Market Insights, Epidemiology and Market Forecast-Market Insights, Epidemiology and Market Forecast-2025 report provides an overview of the disease and in depth research related to Neuroendocrine Carcinoma-Market Insights, Epidemiology and Market Forecast for the 7MM (United States, Germany, France, Italy, Spain and UK) for
Neuroendocrine Tumors Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape. Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part
Neuroendocrine Tumors Pipeline Review H1 2017
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2017, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape. Neuroendocrine tumor begins in the hormone-producing cells of the body's neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part
Global Neuroendocrine Tumor Treatment Market
The Global Neuroendocrine Tumor Treatment Market was valued at US$ 1,197.3 million in 2016 and is projected to expand at a CAGR of 10.5% during the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Better diagnostic techniques and products in pipeline are expected to be major factors driving growth of the global neuroendocrine tumor treatment market over the foreseeable future. Neuroendocrine Tumor (NET) are diagnosed